Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 7.6% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price was up 7.6% during trading on Friday . The stock traded as high as $15.34 and last traded at $14.67. Approximately 413,358 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 610,456 shares. The stock had previously closed at $13.64.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a report on Monday, February 10th. They set a “sell” rating for the company.

Tonix Pharmaceuticals Stock Up 9.9 %

The firm has a market capitalization of $28.01 million, a P/E ratio of 0.00 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock has a 50 day moving average of $19.65 and a 200-day moving average of $20.20.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. PFG Investments LLC bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at about $72,000. Two Sigma Investments LP purchased a new position in Tonix Pharmaceuticals in the 4th quarter worth approximately $66,000. Northern Trust Corp bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $162,000. Jane Street Group LLC grew its position in Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock worth $548,000 after acquiring an additional 1,635,119 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $526,000. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.